| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.21 | 9e-10 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.29 | 2e-08 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.28 | 5e-08 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-07 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.26 | 3e-06 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-05 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.12 | 4e-05 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |